Alpha 2.0
Login Register
» Authors » Tiemei Zhao

Tiemei Zhao

Explore the profile of Tiemei Zhao including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 123
Followers 0
Related Specialties
Pulmonary Medicine
General Medicine
Pharmacology
Top 10 Co-Authors
Youning Liu
Hui Wang
Ping Chen
Bin Cao
Feng Ye
Bei He
Kan Zhang
Tieying Sun
Jun Wu
Baiqiang Cai
Published In
Zhonghua Jie He He Hu Xi Za Zhi
Antimicrob Agents Chemother
J Med Case Rep
BMC Infect Dis
J Thorac Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
Optimized administration of human embryonic stem cell-derived immunity-and-matrix regulatory cells for mouse lung injury and fibrosis
Song D, Li Z, Sun F, Wu K, Zhang K, Liu W, et al.
Stem Cell Res Ther . 2024 Oct; 15(1):344. PMID: 39380037
Background: Lung injury and pulmonary fibrosis (PF), frequently arising as sequelae of severe and acute lung disease, currently face a dearth of effective therapeutic potions. Mesenchymal stem cells (MSCs) with...
2.
Asymptomatic thrombocytopenia after nintedanib initiation in a patient with progressive pulmonary fibrosis: a case report and review of literature
Zhang X, Zhang K, Zhao N, Xi N, Zhao T
J Med Case Rep . 2024 Sep; 18(1):451. PMID: 39342394
Background: Nintedanib is a primary antifibrosing medication available for idiopathic pulmonary fibrosis, systemic sclerosis-interstitial lung disease, and progressive pulmonary fibrosis, with scattered report of drug-induced thrombocytopenia. Case Report: A 60-year-old...
3.
Clinical manifestations and outcome of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody positive patients with interstitial lung disease
Feng L, Wang H, Zhao Y, Zhao T, Zhang J, Huang F, et al.
Clin Exp Rheumatol . 2021 Feb; 40(1):97-103. PMID: 33635220
Objectives: To analyse the clinical features and risk factors of acute/subacute interstitial pneumonia (A/SIP) and death in patients with positive anti-aminoacyl-transfer RNA synthetase antibody (anti-ARS Ab) and positive anti-melanoma differentiation-associated...
4.
A randomized, open, multicenter clinical study on the short course of intravenous infusion of 750 mg of levofloxacin and the sequential standard course of intravenous infusion/oral administration of 500 mg of levofloxacin for treatment of...
Zhao T, Chen L, Wang P, Tian G, Ye F, Zhu H, et al.
J Thorac Dis . 2016 Oct; 8(9):2473-2484. PMID: 27746999
Background: To compare 5-day regimen of levofloxacin 750 mg IV daily with 7-14-day conventional regimen of levofloxacin 500 mg intravenous to oral (IV/PO) daily for treatment of community-acquired pneumonia (CAP)...
5.
Prospective multicenter study of pathogen distributions in early-onset and late-onset hospital-acquired pneumonia in china
Zhao T, Liu Y, Cao B, Wang H, Chen L, She D, et al.
Antimicrob Agents Chemother . 2013 Sep; 57(12):6404-5. PMID: 24041893
No abstract available.
6.
N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa
Zhao T, Liu Y
BMC Microbiol . 2010 May; 10:140. PMID: 20462423
Background: Pseudomonas aeruginosa is a common pathogen in chronic respiratory tract infections. It typically makes a biofilm, which makes treatment of these infections difficult. In this study, we investigated the...
7.
Causative agent distribution and antibiotic therapy assessment among adult patients with community acquired pneumonia in Chinese urban population
Liu Y, Chen M, Zhao T, Wang H, Wang R, Cai B, et al.
BMC Infect Dis . 2009 Mar; 9:31. PMID: 19292931
Background: Knowledge of predominant microbial patterns in community-acquired pneumonia (CAP) constitutes the basis for initial decisions about empirical antimicrobial treatment, so a prospective study was performed during 2003-2004 among CAP...
8.
[Changes in the spectrum of the pathogens of community-acquired pneumonia]
Zhao T, Liu Y
Zhonghua Jie He He Hu Xi Za Zhi . 2003 Apr; 25(12):753-5. PMID: 12678059
No abstract available.